Familial hyperaldosteronism type III.
Monticone S, Tetti M, Burrello J, Buffolo F, De Giovanni R, Veglio F, Williams TA, Mulatero P.
J Hum Hypertens. 2017 Dec;31(12):776-781. doi: 10.1038/jhh.2017.34. Epub 2017 Apr 27.
Familial hyperaldosteronism.
Stowasser M, Gordon RD.
J Steroid Biochem Mol Biol. 2001 Sep;78(3):215-29. doi: 10.1016/s0960-0760(01)00097-8.
Familial hyperaldosteronism.
Torpy DJ, Stratakis CA, Chrousos GP.
Braz J Med Biol Res. 2000 Oct;33(10):1149-55. doi: 10.1590/s0100-879x2000001000004.
Familial forms and molecular profile of primary hyperaldosteronism.
Araujo-Castro M, Martín Rojas-Marcos P, Parra Ramírez P.
Hipertens Riesgo Vasc. 2022 Oct-Dec;39(4):167-173. doi: 10.1016/j.hipert.2022.05.007. Epub 2022 Jun 28.
Familial hyperaldosteronism type III a novel case and review of literature.
Pons Fernández N, Moreno F, Morata J, Moriano A, León S, De Mingo C, Zuñiga Á, Calvo F.
Rev Endocr Metab Disord. 2019 Mar;20(1):27-36. doi: 10.1007/s11154-018-9481-0.
Pathogenesis of Familial Hyperaldosteronism Type II: New Concepts Involving Anion Channels.
Stowasser M, Wolley M, Wu A, Gordon RD, Schewe J, Stölting G, Scholl UI.
Curr Hypertens Rep. 2019 Apr 4;21(4):31. doi: 10.1007/s11906-019-0934-y.
Genetic testing for familial hyperaldosteronism type 1 in Aotearoa/New Zealand.
Elston MS, Tamatea JAU, King RI, Florkowski CM, Boyle V.
Intern Med J. 2024 Nov;54(11):1814-1820. doi: 10.1111/imj.16511. Epub 2024 Aug 31.
Pathophysiology of bilateral hyperaldosteronism.
Nanba K, Rainey WE.
Curr Opin Endocrinol Diabetes Obes. 2022 Jun 1;29(3):233-242. doi: 10.1097/MED.0000000000000729.
Primary aldosteronism.
Gordon RD.
J Endocrinol Invest. 1995 Jul-Aug;18(7):495-511. doi: 10.1007/BF03349761.
Familial hyperaldosteronism I-III.
Quack I, Vonend O, Rump LC.
Horm Metab Res. 2010 Jun;42(6):424-8. doi: 10.1055/s-0029-1246187. Epub 2010 Feb 3.
